The Hidden Risk in Common Liver Disease
MASLD affects about one in four people worldwide. Most never feel sick. Many don’t even know they have it. For years, doctors assumed liver cancer was rare in these patients unless cirrhosis was present. But this new research suggests the danger starts earlier.
Liver cancer, or hepatocellular carcinoma (HCC), is often caught too late. Survival rates are low. Yet screening has been limited to those with cirrhosis. This study says we may need to look sooner.
Scarring Matters More Than We Thought
The big finding? Advanced fibrosis—significant scarring, but not full cirrhosis—raises liver cancer risk sharply. In large database studies, people with MASLD and advanced fibrosis had an 8.8% chance of developing liver cancer within 10 years. In hospital-based studies, that number jumped to 48.5%.
That difference is important. Database studies track broad populations. Hospital studies follow sicker patients. But both agree: scarring means higher risk.
Even without advanced fibrosis, some risk remains. In hospital settings, 18.3% of MASLD patients without severe scarring still developed liver cancer in 10 years. But the risk is far lower in general populations—just 1.3%.
Why the Big Difference in Risk?
Think of the liver like a busy factory. When fat builds up, the machines get clogged. Over time, repairs create scar tissue. A little scarring is like minor wear and tear. But advanced fibrosis is like cracked pipes and broken belts. The system becomes unstable. Cells start making errors. Some errors lead to cancer.
The study used data from 26 studies and nearly 4 million people. Researchers rebuilt individual timelines from published graphs to get more accurate estimates. This method is not perfect, but it gives a clearer picture than ever before.
Patients were followed over time. Some came from insurance records. Others from liver clinics. The clinic patients were sicker to begin with. That likely explains the higher cancer rates there.
Cancer Risk Rises with Scarring
The numbers tell a clear story. For those with advanced fibrosis, the risk of liver cancer is 10 times higher than for those without it. That’s true in both real-world data and clinical settings.
At one year, the cancer rate was 0.8% in database studies and 3.9% in clinic studies. By 10 years, it reached 8.8% and 48.5%, respectively. That’s a big jump.
For patients without advanced scarring, the risk stays low. In general populations, it’s just 1.3% over 10 years. But in clinics, it’s 18.3%. This suggests that other factors—like inflammation or genetics—may also play a role.
But there's a catch.
This doesn't mean this treatment is available yet.
These findings don’t change current treatment. There’s no new drug. But they could change how often patients get checked.
Experts say this data supports earlier and more frequent liver cancer screening for MASLD patients with advanced fibrosis. Right now, many don’t qualify unless they have cirrhosis.
What This Means for Patients
If you have MASLD, talk to your doctor about your fibrosis stage. A simple scan or blood test can estimate scarring. If you have advanced fibrosis, you may need ultrasounds every six months to catch cancer early.
But not everyone with MASLD needs this. For most, the risk remains low. The goal is to focus on those who need it most.
Study Has Limits but Points Forward
The data came from different sources with different methods. Some studies followed patients for years. Others were shorter. The reconstructed data method is strong, but not the same as having raw patient records.
Also, most participants were from high-income countries. Results may differ elsewhere.
Still, this is the largest analysis of its kind. It confirms a growing concern: MASLD is not always harmless.
What Happens Next
Doctors and health groups may now rethink liver cancer screening rules. Clinical trials could test whether earlier monitoring saves lives. For now, the message is clear: liver health matters, and scarring is a red flag worth watching.
